WO2019123294A3 - Nouvelles utilisations de dérivés pyrazolo pipéridine - Google Patents

Nouvelles utilisations de dérivés pyrazolo pipéridine Download PDF

Info

Publication number
WO2019123294A3
WO2019123294A3 PCT/IB2018/060309 IB2018060309W WO2019123294A3 WO 2019123294 A3 WO2019123294 A3 WO 2019123294A3 IB 2018060309 W IB2018060309 W IB 2018060309W WO 2019123294 A3 WO2019123294 A3 WO 2019123294A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolo
treatment
lupus erythematosus
systemic lupus
pyrimidine derivatives
Prior art date
Application number
PCT/IB2018/060309
Other languages
English (en)
Other versions
WO2019123294A2 (fr
Inventor
Jonathan DEANE
Tobias Junt
Pius Loetscher
Barbara Nuesslein-Hildesheim
Ben Wen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to CN201880078211.3A priority Critical patent/CN111432818A/zh
Priority to JP2020533229A priority patent/JP2021507889A/ja
Publication of WO2019123294A2 publication Critical patent/WO2019123294A2/fr
Publication of WO2019123294A3 publication Critical patent/WO2019123294A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

La présente invention concerne l'utilisation de certains dérivés pyrazolo pipéridine dans le traitement de maladies et d'états associés à l'interaction du récepteur de type toll. Plus particulièrement, ledit traitement est un traitement de lupus neuropsychiatrique (NPSLE).
PCT/IB2018/060309 2017-12-22 2018-12-19 Nouvelles utilisations de dérivés pyrazolo pipéridine WO2019123294A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880078211.3A CN111432818A (zh) 2017-12-22 2018-12-19 用于治疗神经精神性系统性红斑狼疮的吡唑并哌啶衍生物和吡唑并嘧啶衍生物
JP2020533229A JP2021507889A (ja) 2017-12-22 2018-12-19 ピラゾロピペリジン誘導体の新規な使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17210059.6 2017-12-22
EP17210059 2017-12-22
US201862769635P 2018-11-20 2018-11-20
US62/769,635 2018-11-20

Publications (2)

Publication Number Publication Date
WO2019123294A2 WO2019123294A2 (fr) 2019-06-27
WO2019123294A3 true WO2019123294A3 (fr) 2019-08-01

Family

ID=65201642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/060309 WO2019123294A2 (fr) 2017-12-22 2018-12-19 Nouvelles utilisations de dérivés pyrazolo pipéridine

Country Status (3)

Country Link
JP (1) JP2021507889A (fr)
CN (1) CN111432818A (fr)
WO (1) WO2019123294A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019155042A1 (fr) 2018-02-12 2019-08-15 F. Hoffmann-La Roche Ag Nouveaux composés et dérivés de sulfone pour le traitement et la prophylaxie d'une infection virale
WO2019238616A1 (fr) 2018-06-12 2019-12-19 F. Hoffmann-La Roche Ag Nouveaux composés hétéroarlyle hétérocyclyle pour le traitement d'une maladie auto-immune
CN112584903A (zh) 2018-07-23 2021-03-30 豪夫迈·罗氏有限公司 用于自身免疫性疾病治疗的新型哌嗪化合物
CN112638908A (zh) 2018-09-04 2021-04-09 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的苯并噻唑类化合物
JP2022502353A (ja) 2018-09-06 2022-01-11 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の処置のための新規の環状アミジン化合物
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
TW202337443A (zh) * 2022-01-11 2023-10-01 瑞士商諾華公司 使用ｔｌｒ７／８拮抗劑治療ｓｊｏｇｒｅｎ氏症候群或混合性結締組織病之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057655A1 (fr) * 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Composés de quinoléine substitués de manière sélective
WO2018047081A1 (fr) * 2016-09-09 2018-03-15 Novartis Ag Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
KR101865120B1 (ko) 2016-06-29 2018-06-08 숭실대학교 산학협력단 테스트 노드 기반의 무선 측위 방법 및 그 장치

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057655A1 (fr) * 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Composés de quinoléine substitués de manière sélective
WO2018047081A1 (fr) * 2016-09-09 2018-03-15 Novartis Ag Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLISON R. BIALAS ET AL: "Microglia-dependent synapse loss in type I interferon-mediated lupus", NATURE, 14 June 2017 (2017-06-14), GB, XP055476303, ISSN: 0028-0836, DOI: 10.1038/nature22821 *
CÉSAR MAGRO-CHECA ET AL: "Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives", DRUGS, vol. 76, no. 4, 26 January 2016 (2016-01-26), NZ, pages 459 - 483, XP055476422, ISSN: 0012-6667, DOI: 10.1007/s40265-015-0534-3 *
WANG H P ET AL: "Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 607, no. 1-3, 1 April 2009 (2009-04-01), pages 102 - 106, XP026007773, ISSN: 0014-2999, [retrieved on 20090304], DOI: 10.1016/J.EJPHAR.2009.02.039 *

Also Published As

Publication number Publication date
WO2019123294A2 (fr) 2019-06-27
CN111432818A (zh) 2020-07-17
JP2021507889A (ja) 2021-02-25

Similar Documents

Publication Publication Date Title
WO2019123294A3 (fr) Nouvelles utilisations de dérivés pyrazolo pipéridine
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
WO2017201132A3 (fr) Pyrrolobenzodiazépines et leurs conjugués
WO2016196776A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
EP3481831A4 (fr) Nouveaux dérivés de 4-aminopyrazolo [3,4-d]pyrimidinylazabicyclo et compositions pharmaceutiques les contenant
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
WO2016205531A3 (fr) Anticorps anti-her2 et leurs procédés d'utilisation
WO2016004305A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2017214170A3 (fr) Anticorps baff-r et utilisations de ceux-ci
WO2018067520A3 (fr) Procédés et agents thérapeutiques
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
EP3660019C0 (fr) 7h-pyrazolo[3,4-d]triazine-2-oxides en tant qu'explosifs
EP3730492A4 (fr) Composé pyrazolo[1,5-a]pyrimidine substitué, composition pharmaceutique et utilisation associée
EP3765521A4 (fr) Anticorps anti-récepteur 1 aux folates et leurs utilisations
WO2015195863A8 (fr) 2-((4s)-6-(4-chlorophényl)-1-méthyl-4h-benzo[c]isoxazolo[4,5-e]azépine-4-yl)acétamide hydraté
EP3470480A4 (fr) Procédé d'obtention de nitrocellulose dans laquelle des agglutinants (binders) sont incorporés, nitrocellulose dans laquelle des agglutinants (binders) sont incorporés, et son utilisation
IL262711A (en) History of a [3,2,1]triazolo[5,4-d]pyrimidine with affinity for the type 2 cannabinoid receptor
EP3653614A4 (fr) Dérivé de tétrahydronaphto[1,2-b]furan-2(3h)-one, sa préparation et son utilisation dans des produits pharmaceutiques
WO2018013951A9 (fr) Ciblage des récepteurs a2a de l'adénosine pour le traitement de dyskinésies induites par la lévodopa
EP3310358A4 (fr) Compositions et procédés pour le traitement de troubles d'utilisation de substances, d'accoutumance, et de troubles psychiatriques
EP3546458A4 (fr) Dérivé de pyrido[3, 4-d]pyrimidine et sel pharmaceutiquement acceptable de celui-ci
IT201600130012A1 (it) Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale
Russo The toxic well of loneliness
EP3675890A4 (fr) Améliorations de l'analyse d'igf-1, de l'ajustement et de la gestion de maladie d'états non neurologiques et/ou neurologiques
EP3551648A4 (fr) Agents de liaison à un ligand du récepteur du facteur neurotrophique ciliaire et leurs méthodes d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18839619

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020533229

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18839619

Country of ref document: EP

Kind code of ref document: A2